Replimune Group (REPL) Nosedives 39% as FDA Approval ... - Finviz
Stock screener for investors and traders, financial visualizations.
finviz.comHere’s a concise update on Replimune Inc. (REPL) based on the latest publicly available reporting.
-
FDA status and recent news: Replimune’s lead candidate RP1 in combination with nivolumab faced regulatory challenges. A Complete Response Letter (CRL) from the FDA in April 2026 for the RP1 BLA in advanced melanoma has been reported, with the agency questioning the viability of accelerated approval without clearer data. This development has been associated with market weakness and strategic adjustments at the company, including cost-cutting and manufacturing scale-back plans in the U.S.[1][3]
-
Corporate and financial updates: Following the FDA communications, Replimune has disclosed ongoing efforts to reassess path forward, including potential financing options and timelines tied to any resubmission or alternate regulatory pathway. In addition, the company has referenced discussions around the IGNYTE data and potential contributions from ongoing trials to support future regulatory decisions. Cash and liquidity specifics have varied across reports, with notable cash runway cited in mid-2025 and subsequent updates focusing on new funding arrangements and debt considerations.[3][5][1]
-
Market reaction: The company’s shares have experienced substantial volatility around regulatory milestones, including a notable decline when regulatory clarity was reduced or delays were announced. Investor sentiment has been heavily influenced by the FDA feedback and the perceived impact on RP1’s commercial potential.[2]
-
What to watch next: Key near-term milestones include any FDA communications or guidance on a resubmission timeline, further updates from ongoing or planned trials (e.g., IGNYTE program variants), and any new financing or strategic partnerships that could extend runway or alter plans for RP1.[5]
If you’d like, I can pull the most recent press releases or regulatory filings to provide exact dates and quotes, and/or summarize the latest earnings or conference presentations. I can also provide a brief timeline of RP1-related events up to today.
Citations:
- Latest news and corporate updates mentioning the CRL, PDUFA date references, and restructuring comments[1]
- Market reaction and regulatory feedback coverage[2]
- Specific summaries of the April 2026 FDA communication and follow-on corporate actions[3][5]